Goldman Sachs’s Cellebrite CLBT Stock Holding History
Bought
Maintained
Sold
Other funds holding CLBT
TWCM
VC
PP
PF
NTCM
CI
Goldman Sachs's CLBT Position: Q2 2026 in Review
Goldman Sachs increased its Cellebrite (CLBT) stake by 122% in Q2 2026, buying an estimated $4.31M and bringing the position to 591,842 shares worth $8.64M. The position accounts for ﹤0.01% of the portfolio, ranked #3377.
Goldman Sachs first reported a position in CLBT in Q4 2021 and has held it in 19 quarters since. The position peaked at $16.1M in Q2 2024. 201 funds tracked by Wall St. Rank hold CLBT as of Q2 2026.
- Goldman Sachs held 591,842 shares of Cellebrite worth $8.64M as of Q2 2026.
- Goldman Sachs bought 325,776 Cellebrite shares in Q2 2026, an estimated $4.31M.
- Cellebrite made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3377 holding.
- Goldman Sachs first reported a position in Cellebrite in Q4 2021 and has held it in 19 quarters since.
- Goldman Sachs's Cellebrite position peaked at $16.1M in Q2 2024.
- 201 funds tracked by Wall St. Rank held Cellebrite as of Q2 2026.
Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.